Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CCKBR | P32239 | 2/20 | 0.40 |
| ▸ | CCKAR | P32238 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
| ▸ | ITGAL | P20701 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6495989 | 0.89 | MAPT (0.45) | — | |
| SCHEMBL6483067 | 0.88 | HPGDS (0.44) | MEN1KMT2ANPBWR1MCHR1HCRTR1 | |
| SCHEMBL6480725 | 0.87 | CA12 (0.42) | KMT2ACA12CA1CA9CCKBR | |
| SCHEMBL6480650 | 0.83 | GHSR (0.51) | — | |
| SCHEMBL6481196 | 0.80 | MMP9 (0.43) | KMT2ACA12CA1CA9 | |
| SCHEMBL6481850 | 0.79 | MEN1 (0.45) | MEN1KMT2AITGB2ICAM1ITGAL | |
| SCHEMBL6488832 | 0.79 | MMP9 (0.43) | KMT2ACA12CA1CA9HPGDS | |
| SCHEMBL6482403 | 0.78 | HDAC6 (0.43) | KMT2A | |
| SCHEMBL6484182 | 0.76 | MMP1 (0.50) | — | |
| SCHEMBL6481346 | 0.75 | MMP9 (0.43) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261332-A1 | Sulfonamides and uses thereof | ELIXIR PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261332-A1 | Sulfonamides and uses thereof | GLS2, STS, ABAT | MEN1 1857/4885KMT2A 1732/4885NPBWR1 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.